Effect of Stellate Ganglion Block on Sleep Quality in Patients With Depression
# Brief Summary
This clinical research study looks at whether stellate ganglion block (SGB) can improve sleep quality for people with depression. Poor sleep often goes together with depression. Medicines used for these conditions may cause side-effects or dependency. Researchers want to learn if SGB, a minimally-invasive nerve treatment, can help sleep and mood without those medicine-related downsides.
This study uses a self-controlled design. Every person who joins will receive the study treatment. No separate comparison group is enrolled. Researchers will collect sleep data from each participant before treatment and again after treatment, then compare these two sets of information.
About 42 participants will take part in this study.
Key requirements to join the study:
- Aged 18 to 65 years old
- Have depression-related symptoms and sleep trouble
- Able to understand and sign an informed consent form
- No medical conditions that make SGB unsafe
- Have not taken sleep-affecting medicines or received other sleep-focused treatments in the past one month
- Can follow study schedules and complete all study assessments
People cannot join if they:
- Are younger than 18 years or older than 65 years
- Are pregnant or breastfeeding
- Have known allergies to study-used medicines
- Have unstable serious organ diseases, uncontrolled substance or alcohol dependence
- Cannot keep fixed daily routines or finish all study visits
Study procedures for each participant:
- On study day zero (D0): Study staff will explain the study fully. Participants will sign informed consent. Staff will run physical checks and blood tests. Participants will fill out several simple questionnaires about mood and sleep. Sleep will be measured overnight with a multi-channel sleep recording device called polysomnography (PSG). Participants also keep a short sleep diary.
- From study day one (D1) to day five (D5): Participants get one SGB treatment each day, for a total of five treatments. During SGB, a doctor uses ultrasound guidance to inject small-dose local anesthetic near nerves in the neck. Participants keep completing their sleep diary every day. Study staff watch for any unwanted reactions during each treatment.
- On the night of D5 through early morning of D6: PSG sleep recording will be repeated after the final SGB treatment.
- On study day six (D6): Participants finish the final set of mood-and-sleep questionnaires. Study staff collect all safety information.
Researchers will compare sleep measurements taken before treatment versus after five-day SGB treatment. Collected data includes objective sleep readings from PSG and self-reported sleep information from sleep diaries. Questionnaires will show changes in depression and insomnia symptoms.
Possible benefits: SGB may make participants' sleep better and may ease depression-related symptoms. No benefit is guaranteed for every participant.
Possible risks: SGB is generally safe. Rare unwanted reactions may include temporary hoarseness, local neck-site infection, or drug allergic responses. Study doctors will watch participants closely. If serious problems happen, immediate medical help will be provided.
All participants' private personal information will be protected. Participants can choose to stop taking part in this research at any time without penalty.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: tong fu, Master
- Telefonnummer: +8613156561090
- E-Mail: futong5533227@126.com
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Aged 18-65 years of both genders. Alert and capable of normal communication. Voluntarily sign informed consent, complete the whole experimental procedure, and meet ethical and compliance requirements.
- Hamilton Depression Rating Scale (HAMD) score ≥ 8.
- Insomnia Severity Index (ISI) score ≥ 7 or Pittsburgh Sleep Quality Index (PSQI) score ≥ 7.
- No contraindications to stellate ganglion block (SGB); no cervical deformity, trauma, or infection; and no severe cervical spine disease, such as cervical fracture or cervical disc herniation with nerve compression.
- No use of sedative-hypnotics, anxiolytics, antidepressants, or other medications that may affect sleep within the past month, and no acupuncture, massage, nerve block, or other sleep-related interventions during the same period.
- Stable vital signs; normal liver and renal function, complete blood count, and coagulation function; and no severe organic diseases of the heart, brain, lungs, liver, or kidneys.
- Able to strictly follow the required sleep-wake schedule and cooperate with polysomnography (PSG) monitoring and completion of sleep diaries, with good study compliance.
Exclusion Criteria:
-
1: Age <18 or >65 years; pregnant or lactating women; subjects with psychiatric disorders (schizophrenia, mania, etc.) or cognitive impairment who cannot cooperate with the study, to prevent missing data and experimental bias.
2: Presence of contraindications to stellate ganglion block, such as coagulation disorders, local skin infection, severe cervical spine disease, hyperthyroidism, glaucoma, or increased intracranial pressure.
3: Allergy to ropivacaine, epinephrine, or other drugs used for the block, or a history of drug allergy.
4: Use of sedative-hypnotics, anxiolytics, antidepressants, hormonal medications, or other treatments that may affect sleep within the past month.
5: Severe cardiovascular or cerebrovascular disease, hepatic or renal insufficiency, hematologic disease, respiratory disease, or other serious organic diseases, or a recent history of surgery or trauma.
6: Alcohol dependence or drug dependence, or daily consumption of coffee, strong tea, or other stimulating beverages with inability to abstain during the study period.
7: Inability to maintain a fixed sleep-wake schedule during the study or inability to complete the full monitoring and intervention procedures because of work, daily life, or other reasons.
8: Voluntary withdrawal during the study, or inability to complete the study because of adverse reactions, poor compliance, or other reasons.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: SGB group
Stellate Ganglion Block |
Using an anterior-lateral approach, participants lie supine with head turned contralaterally to expose the neck. The interspace between the anterior sternocleidomastoid border, trachea and common carotid artery is identified. Skin is disinfected 3 times with iodophor (≥15 cm diameter), then covered with a sterile aperture drape. A 22-G needle is inserted vertically at the target site. After bony contact with the C6 transverse process, the needle is retracted 0.1-0.2 cm. With negative aspiration for blood and cerebrospinal fluid, inject 6 mL 0.25% ropivacaine (epinephrine 1:200 000) at 1 mL/min to limit bleeding and prolong block effect. Monitor blood pressure, heart rate, oxygen saturation, and adverse events (hoarseness, Horner syndrome, dyspnea) throughout injection. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Sleep Onset Latency, SOL
Zeitfenster: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
|
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
|
|
Wake After Sleep Onset, WASO
Zeitfenster: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
|
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
|
|
Total Sleep Time, TST
Zeitfenster: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
|
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
|
|
Proportions of each non-rapid eye movement sleep stage
Zeitfenster: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
|
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
|
|
Proportions of REM, NREM and Wake
Zeitfenster: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
|
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
|
|
Sleep Efficiency, SE
Zeitfenster: At baseline (Day 0) and from Night 5 to Morning 6 after intervention
|
At baseline (Day 0) and from Night 5 to Morning 6 after intervention
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Subjective sleep-onset latency
Zeitfenster: 30 minutes after awakening on the corresponding next morning
|
30 minutes after awakening on the corresponding next morning
|
|
Subjective Total Sleep Time
Zeitfenster: 30 minutes after awakening on the corresponding next morning
|
30 minutes after awakening on the corresponding next morning
|
|
Subjective Sleep Efficiency
Zeitfenster: 30 minutes after awakening on the corresponding next morning
|
30 minutes after awakening on the corresponding next morning
|
|
Sleep Satisfaction
Zeitfenster: 30 minutes after awakening on the corresponding next morning
|
30 minutes after awakening on the corresponding next morning
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Liu Y, Liu L, Deng Z, Zhou Y, Xiao L, Tang Y. Application of stellate ganglion modulation in mental disorders and the future prospects of physical therapies. Fundam Res. 2025 Oct 23;6(1):548-559. doi: 10.1016/j.fmre.2025.09.024. eCollection 2026 Jan.
- Plante DT. The Evolving Nexus of Sleep and Depression. Am J Psychiatry. 2021 Oct 1;178(10):896-902. doi: 10.1176/appi.ajp.2021.21080821.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- BoYi Medical Ethics No.1162026
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
De-identified individual participant data underlying the published results will be available to qualified researchers after article publication. Data access requires a formal research proposal and signed data-use agreement.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .